Adage Capital Partners’s Caribou Biosciences CRBU Stock Holding History

Adage Capital Partners’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-153,933	Closed	-$791K	–	881
2024 Q1	$791K	Sell	153,933 -50,000	-25%	-$308K	﹤0.01%	799
2023 Q4	$1.17M	Sell	203,933 -50,000	-20%	-$247K	﹤0.01%	758
2023 Q3	$1.21M	Hold	253,933	–	–	﹤0.01%	759
2023 Q2	$1.08M	Sell	253,933 -33,100	-12%	-$149K	﹤0.01%	766
2023 Q1	$1.52M	Hold	287,033	–	–	﹤0.01%	782
2022 Q4	$1.8M	Sell	287,033 -60,000	-17%	-$534K	﹤0.01%	821
2022 Q3	$3.66M	Sell	347,033 -25,000	-7%	-$233K	0.01%	812
2022 Q2	$2.02M	Sell	372,033 -237,034	-39%	-$1.81M	﹤0.01%	879
2022 Q1	$5.59M	Hold	609,067	–	–	0.01%	819
2021 Q4	$9.19M	Hold	609,067	–	–	0.02%	724
2021 Q3	$14.5M	Buy	+609,067	New	+$14.9M	0.03%	579

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners's CRBU Position: Q2 2024 in Review

Adage Capital Partners sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 153,933 shares — an estimated $791K sold.

Adage Capital Partners first reported a position in CRBU in Q3 2021 and held it in 11 quarters. The position peaked at $14.5M in Q3 2021. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

Adage Capital Partners reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
Adage Capital Partners sold 153,933 Caribou Biosciences shares in Q2 2024, an estimated $791K.
Adage Capital Partners first reported a position in Caribou Biosciences in Q3 2021 and held it in 11 quarters.
Adage Capital Partners's Caribou Biosciences position peaked at $14.5M in Q3 2021.
140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Adage Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.